Archives
-
JXY, TLR4, and M1 Macrophages in CAC
2026-09-22
The reference study shows that Jiedu Xiaozheng Yin (JXY) restrains colitis-associated colorectal cancer by shifting intestinal macrophages toward an M1 phenotype through TLR4-associated signaling. Its integrated animal, histological, immunohistochemical, flow-cytometric, and gene-expression analyses support immune-microenvironment modulation as a mechanism of disease control, while pharmacological pathway antagonism provides a basis for examining AP-1-related signaling.
-
PR-619: Reversible DUB Inhibitor Workflows
2026-09-21
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor that separates DUB-dependent ubiquitin accumulation from direct proteasome blockade. This guide translates that distinction into practical workflows for ubiquitination pathway research, autophagy assays, cancer biology, and neurodegenerative disease models.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-09-21
Track both where an mRNA formulation goes and whether it produces functional protein with one dual-reporter transcript. This workflow combines Cy5 fluorescence, luciferase bioluminescence, and formulation-aware controls for transfection optimization, trafficking studies, and preclinical nasal delivery research.
-
Hyaluronic Acid Sodium Salt in Translational siRNA
2026-09-20
Hyaluronic acid sodium salt is evolving from an extracellular matrix material into a strategic interface for siRNA delivery, immune-cell modulation, and translational infection research. This article connects its matrix biology with a recent HA-coated nanoparticle study targeting TDRD9 in Pseudomonas aeruginosa lung injury, while outlining practical formulation, validation, and clinical-readiness considerations.
-
Omeprazole A2845: Gastric Acid Research Guide
2026-09-19
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related assay development. This dossier-based guide covers identity, solvent handling, storage, assay interpretation, and QC; the material is for scientific research only and is not intended for diagnostic or medical use.
-
Oridonin, Inflammation, and Esophageal Cancer
2026-09-18
This 2025 study investigates whether oridonin counteracts esophageal cancer through the TLR4/NF-κB/NLRP3 inflammasome axis in a 4-NQO mouse model. Its main contribution is the integration of histopathology, systemic inflammatory markers, blood-cell indices, and cancer-related molecular endpoints, while its findings remain preclinical and mechanistic rather than clinical.
-
WM-8014 and the Logic of Epigenetic State Control
2026-09-18
WM-8014 offers translational researchers a reversible, competitive way to interrogate KAT6A/B-dependent growth control, senescence, and oncogenic proliferation. This thought-leadership guide connects its biochemical mechanism and model-system evidence with time-gated functional genomics, experimental design, and development strategy.
-
BGJ398 and the Translational Logic of FGFR Biology
2026-09-17
A mechanistic and translational framework for using BGJ398 (NVP-BGJ398) to interrogate FGFR-dependent cancer biology, pathway selectivity, and developmental context.
-
Dual HER2–VEGFR2 Targeting in TNBC
2026-09-17
The reference study examines lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation support further pathway-focused investigation, but the in vitro findings do not establish target engagement, pharmacological synergy, or clinical efficacy.
-
Phosphatase Inhibitor Cocktail 1 Workflow Guide
2026-09-16
Protect labile phosphorylation signals from harvest through analysis with a practical workflow built around Phosphatase Inhibitor Cocktail 1. The guide differentiates sample-preservation use in Western blotting, immunoprecipitation, kinase assays, and phosphoproteomic analysis from applications where inhibitor carryover can distort enzyme measurements.
-
TDRD9 siRNA Nanoparticles in P. aeruginosa Lung Injury
2026-09-16
The reference study identifies TDRD9 as a suppressor of neutrophil cuproptosis during Pseudomonas aeruginosa lung infection and develops hyaluronic acid-coated peptide nanoparticles for siRNA delivery. Across human samples, mouse models, and human lung organoids, TDRD9 silencing reduced neutrophil accumulation, pulmonary inflammation, and tissue injury while improving infection-associated outcomes.
-
Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
2026-09-15
Phosphatase Inhibitor Cocktail (2 Tubes, 100X) helps limit dephosphorylation during protein extraction and downstream analysis. It is intended for controlled research workflows such as immunoblotting, immunoprecipitation, kinase assays, and mass spectrometry, but it is not a diagnostic or medical reagent and requires assay-specific compatibility checks.
-
RNA Pol II Loss Activates Apoptosis: 2025 Study
2026-09-15
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic response to loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional shutdown alone. Their genetic and chemogenetic analyses define the Pol II degradation-dependent apoptotic response and suggest a mechanism that may contribute to the activity of multiple anticancer compounds.
-
Gamma-Linolenic Acid (GLA) Workflows
2026-09-14
Build more informative inflammation studies by connecting GLA receptor biology with functional cell and apoptosis readouts. This practical guide covers stock preparation, dose design, assay controls, translational modeling, and troubleshooting for reproducible anti-inflammatory research.
-
YC-1: HIF-1α and sGC Research Guide
2026-09-14
A scenario-driven guide to using YC-1 in hypoxia, viability, proliferation, and cytotoxicity workflows. It explains how SKU B7641 supports controlled formulation, mechanism-aware interpretation, and reproducible assay design without overstating cell-specific potency.